Syntec Optics (OPTX) announced a significant expansion of its space products offering to add optomechanicals for satellite optics and ground ...

Company issued its 2024 Annual Report to Shareholders and announced the date for its 2025 Annual General Meeting. The ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

We expect Teradyne to maintain a strong balance sheet and continue generating robust free cash flow while keeping minimal to no leverage. As of Dec. 31, 2024, Teradyne held a net cash position, with ...